

Media Release

Hyphens Pharma Signs Exclusive Distribution Agreement with Lundbeck for Vietnam

Highlights:

- Exclusive distribution agreement for marketing and distribution of products specific to central nervous system for the Vietnam market.
- Lundbeck is a renowned global pharmaceutical company specialising in treatment of brain diseases.

Singapore, 30 May 2019 – Hyphens Pharma International Limited (“凯帆药剂国际有限公司”, “Hyphens Pharma”, or the “**Company**”, and together with its subsidiaries, the “**Group**”), Singapore’s leading specialty pharmaceutical and consumer healthcare group, entered into an exclusive distribution agreement with H. Lundbeck A/S Group (“**Lundbeck**”) for the marketing and distribution of products in Vietnam. These products are targeted at the treatment of disorders in the central nervous system.

Executive Chairman and CEO, Mr Lim See Wah, (“林世华”) commented: “Lundbeck and Hyphens share the same commitment towards providing a better quality of life for the masses, and through this exclusive partnership, we will be bringing world class healthcare treatments to the Vietnamese public. At the same time, we are also delighted to be able to forge a collaboration with Lundbeck, a globally renowned player in the pharmaceutical domain. We will continue to source for innovative products to enhance our specialty pharma principals portfolio.”

Managing Director, Lundbeck South East Asia, Morten Bryde Hansen says “Lundbeck is very pleased with our new partnership with Hyphens and our entrance into Vietnam - in line with our strategy ‘Expand and Invest to Grow’. Lundbeck has a solid foothold in most Asian markets

and welcome the opportunity to make our products available in Vietnam and to leverage Hyphens' network and infrastructure. We will strive to help and support the Vietnamese patients, to improve brain health and to bring new and innovative treatments to the patients.

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centres in Denmark and California and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18.1 billion in 2018 (EUR 2.4 billion; USD 2.8 billion).

For more information on Lundbeck

Please visit: <https://www.lundbeck.com> or contact Mr Morten Bryde Hansen, Managing Director, Lundbeck Singapore Pte Ltd., tel: (65) 6255 6002 or email: mbh@lundbeck.com

End.

About Hyphens Pharma International Limited (<https://www.hyphensgroup.com/>)

Hyphens Pharma International Limited and its subsidiaries (the "**Group**") is one of Singapore's leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering six additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia, Oman and Bangladesh.

Singapore is the Group's regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group's core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart and Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

Issued on behalf of the Company by Cogent Communications Pte Ltd.
For enquiries, please contact:

Ms Melissa Sim, Tel: (65) 6704-9287, Mob: (65) 9380-2938
Email: melissasim@cogentcomms.com

Mr Gerald Woon, Tel: (65) 6704-9268, Mob: (65) 9694-8364
Email: woon@cogentcomms.com

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.